Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series
2024-514012-28-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ambroxol in Gaucher disease type 3, sponsored by Amsterdam University Medical Center. Planned start Nov 2024; status: authorised.
02
Drugs
ambroxol
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on 2024-514012-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514012-28-00.